Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07716176 Dexamethasone Sodium Phosphate Nausea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07716176 clinical trial report covering Dexamethasone Sodium Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
NCT07717892 Solriamfetol Hydrochloride Attention Deficit Disorder With Hyperactivity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07717892 clinical trial report covering Solriamfetol Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260334 Secutrelvir COVID-19 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
JPRN-jRCT2031260334 clinical trial report covering Secutrelvir, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07717879 Solriamfetol Hydrochloride Attention Deficit Disorder With Hyperactivity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07717879 clinical trial report covering Solriamfetol Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07716449 QLS-31905 CLDN18.2 positive Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07716449 clinical trial report covering QLS-31905, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07716098 Esketamine Hydrochloride Depressive Disorder, Treatment-Resistant Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07716098 clinical trial report covering Esketamine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262832 TARLATAMAB-DLLE Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262832 clinical trial report covering TARLATAMAB-DLLE, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262668 Ferric Maltol Crohn Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262668 clinical trial report covering Ferric Maltol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07720583 Jinhua Qinggan Granules Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720583 clinical trial report covering Jinhua Qinggan Granules, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07719855 Lenalidomide Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07719855 clinical trial report covering Lenalidomide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07720284 Rilvegostomig Muscle Invasive Bladder Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720284 clinical trial report covering Rilvegostomig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07719543 Lenalidomide Immunoglobulin G4-Related Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07719543 clinical trial report covering Lenalidomide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.